VA-NEUSTAR-INC.
Neustar Inc., a global information services and technology company and leader in identity resolution, today announces the redesign of the company’s Partner Program, renamed ‘Ultra Secure Partner Program’ (USPP). Providing enhanced channel access to its unmatched range of cloud-based security solutions, globally distributed network, and mature family of security services, partners can now easily curate and grow their cloud security portfolios.
In addition, Neustar Security Solutions also announces the appointment of Jeremy Nicholls as Vice President of Global Channels. The move comes as part of a wider effort to further grow the company’s channel business.
Ahead of joining Neustar in January 2021, Jeremy was Vice President of Global Channels & Alliances at Arbor Networks for 9 years. He has also held channel and direct sales leadership roles at Niksun, Polycom, and Ericsson and holds an MBA from Bath University in the UK.
Ultra Secure Partner Program
The newly designed program provides a clearly defined tiered structure for its partners to operate within, ensuring clarity on expectations from both parties, with consistent practices, policies, and discounts. Now a standardized, tiered program, the USPP offers varying benefits and expectations to partners depending upon the commitment made, with benefits increasing in higher tiers.
Higher levels of partnership have benefits including, but not limited to: higher discounting, qualified sales leads, training and support, account mapping, access to Neustar specialists and expertise, and focused marketing support, such as promotional materials, customizable collateral, special program funding, and case studies, to help partners generate more business. Discounts offered throughout the program have been increased to afford leading margins to partners, with rates varying by partner tier and reflective of partner engagement levels.
“We’ve reimagined Neustar Security Solutions’ partner program to make it as compelling as possible. Now a simple and value-driven program based on partner engagement levels, we offer highly competitive margins and unrivalled support to our partners ,” said Jeremy Nicholls. “As the world continues to move to the cloud, Neustar Security Solutions is uniquely positioned to partner with organisations who want to grow existing, and secure new customers based around cloud security, where they can wrap their own incremental services to the offerings. ”
Ed Lorenzini, CEO, Analyze Corporation said: “Neustar Security Solutions is a trusted partner of Analyze Corporation. This revamped and standardised program makes growing our business easier and even more rewarding. By participating in Neustar’s USPP, we are able to provide our customers with world-leading security solutions, support and insights that map to their cloud needs.”
Güngör Gündoğdu, Managing Director, Inforte added: “In this growing landscape, we at Inforte have found a valued partner in Neustar Security Solutions. By participating in Neustar’s USPP, our work together is smooth and straightforward, from customer registration through to delivery.”
The new channel partner programs are specifically targeted to expand sales and support coverage for Neustar Security Solutions in the United States, Canada, and Europe, with additional opportunities in Latin America and Eastern Europe.
For more information about the program, visit https://www.home.neustar/about-us/partners/security-partners or contact partners@team.neustar for a direct engagement.
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom